All Trials

KEYMAKER-U01 Substudy 01H: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with stage IV nonsquamous NSCLC who have progressed after both anti-PD-(L)1 therapy and platinum-based chemotherapy, randomizing them to receive either raludotatug deruxtecan (a CDH6-targeting antibody-drug conjugate), ifinatamab deruxtecan (a B7-H3-targeting antibody-drug conjugate), or standard docetaxel. Patients with EGFR, ALK, or ROS1 alterations eligible for targeted therapy are excluded.

ClinicalTrials.gov ID: NCT06780085

A Phase III, Randomized, Double-blind, Multicenter, Global Study of Rilvegostomig or Pembrolizumab Monotherapy for the First-line Treatment of Patients With PD-L1-high Metastatic Non-small Cell Lung Cancer (ARTEMIDE-Lung04)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with previously untreated, PD-L1-high metastatic non-small cell lung cancer (any histology, no EGFR/ALK/ROS1 alterations) and compares rilvegostomig, a bispecific antibody targeting PD-1 and TIGIT, to pembrolizumab monotherapy.

ClinicalTrials.gov ID: NCT06868277

KEYMAKER-U01 Substudy 01I: A Phase 2, Randomized, Umbrella Study With Rolling Arms of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with stage IV squamous NSCLC whose disease has progressed after both anti-PD-(L)1 immunotherapy and platinum chemotherapy, randomizing them to either standard docetaxel or investigational antibody-drug conjugates: Raludotatug deruxtecan (targeting CDH6) or Infinatamab deruxtecan (targeting B7-H3).

ClinicalTrials.gov ID: NCT06780098

A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non-Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with newly diagnosed stage IV NSCLC without EGFR, ALK, ROS1, NTRK, BRAF, RET, or other actionable mutations, randomizing them to standard chemotherapy plus either pembrolizumab (PD-1 inhibitor), zimberelimab (PD-1 inhibitor), or zimberelimab combined with domvanalimab (TIGIT inhibitor) as first-line therapy. Eligible patients must have good performance status (ECOG 0-1) and no prior immune checkpoint inhibitor exposure.

ClinicalTrials.gov ID: NCT05502237

A Multicenter, Randomized, Open-label, Phase 2 Study Evaluating the Safety and Efficacy of BMS-986504 Monotherapy in Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion After Progression on Prior Therapies

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Eligible patients are adults with advanced or metastatic NSCLC harboring homozygous MTAP deletion and disease progression after prior systemic therapies; the trial randomizes participants to two oral dosing regimens of BMS-986504, a selective PRMT5 inhibitor that targets MTAP-deleted tumors through synthetic lethality.

ClinicalTrials.gov ID: NCT06855771

A Phase 2, Open-Label Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with advanced or metastatic breast cancer (including triple-negative and HR+/HER2- subtypes) who are ineligible for further anthracyclines, taxanes, PD-1, or PARP inhibitor therapies, and have received prior chemotherapy. Patients are randomized to standard capecitabine or to regimens combining capecitabine with PCS6422, an investigational oral inhibitor of dihydropyrimidine dehydrogenase (DPD) designed to increase 5-FU exposure and potentially enhance anti-tumor activity.

ClinicalTrials.gov ID: NCT06568692

Phase 2 Study of Paclitaxel (NSC #673089) + Ipatasertib (NSC #781451) in Taxane-Refractory Participants With PTEN/AKT-Altered Advanced Non-Breast Solid Tumors: A ComboMATCH Treatment Trial

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: Eligible patients are adults with advanced or metastatic non-breast solid tumors harboring activating PTEN or AKT alterations who have progressed on or within 6 months of taxane-based therapy and have not received prior AKT inhibitors. Participants receive paclitaxel plus ipatasertib, an oral selective pan-AKT inhibitor, until progression or unacceptable toxicity.

ClinicalTrials.gov ID: NCT05554380

A Phase II, Multi-site, Randomized, Open-label Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of BNT327 at Two Dose Levels in Combination With Chemotherapeutic Agents as First- and Second-line Treatment in Triple-negative Breast Cancer

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adults with locally advanced or metastatic triple-negative breast cancer, either treatment-naïve in the metastatic setting or with one prior line of therapy, to receive BNT327 (a bispecific antibody targeting PD-L1 and VEGF-A) in combination with standard chemotherapy agents (nab-paclitaxel, paclitaxel, gemcitabine/carboplatin, or eribulin) as first- or second-line treatment. Patients must have ECOG 0-1, measurable disease, and no significant autoimmune or comorbid conditions.

ClinicalTrials.gov ID: NCT06449222

A Phase III, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy (Paclitaxel, Nab-paclitaxel or Gemcitabine + Carboplatin) in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls patients with PD-L1 positive (CPS ≥10) locally recurrent inoperable or metastatic triple-negative breast cancer, who have not received prior systemic therapy for advanced disease, to compare datopotamab deruxtecan (a TROP2-directed antibody-drug conjugate) with or without durvalumab (a PD-L1 inhibitor) versus investigator’s choice of chemotherapy plus pembrolizumab.

ClinicalTrials.gov ID: NCT06103864

Randomized, Open-Label Study of the Bria-IMT Regimen and Check Point Inhibitor vs Physicians' Choice in Advanced Metastatic Breast Cancer.

Investigational drug late phase

The trial is testing an investigational drug and is at least phase 2, suggesting that the drug has shown promise in phase 1 studies and might have a high chance of working well compared to other investigational drugs.

Active drug

Investigational drug(s) in this trial have shown anticancer activity in clinical trials

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

HealthScout AI summary: This trial enrolls adult patients with advanced or metastatic breast cancer who have failed all standard subtype-appropriate therapies and have no remaining approved treatment options, including those with stable brain metastases. Patients are randomized to receive either physician's choice of chemotherapy or the investigational regimen of Bria-IMT (an allogeneic GM-CSF-secreting irradiated breast cancer cell line designed to stimulate anti-tumor immunity) plus low-dose cyclophosphamide, intradermal interferon-alpha, and the PD-1 inhibitor retifanlimab.

ClinicalTrials.gov ID: NCT06072612